SP600125 protects RGCs from this insult, indicating that JNK activation is a key signaling component that contributes to RGC loss in this model and may be a potential neuroprotective target for the treatment of PACG attacks or other forms of glaucomatous optic neuropathy and retinopathy. The gene discussed is MAPK8; the disease is retinal disorder.